Author:
Chandarlapaty S,Scaltriti M,Angelini P,Ye Q,Guzman M,Hudis C A,Norton L,Solit D B,Arribas J,Baselga J,Rosen N
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference42 articles.
1. Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J et al. (2006). Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 25: 3234–3244.
2. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J . (1998). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825–2831.
3. Basso AD, Solit DB, Munster PN, Rosen N . (2002). Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21: 1159–1166.
4. Benezra R, Henke E, Ciarrocchi A, Ruzinova M, Solit D, Rosen N et al. (2005). Induction of complete regressions of oncogene-induced breast tumors in mice. Cold Spring Harb Symp Quant Biol 70: 375–381.
5. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K et al. (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395–402.
Cited by
104 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献